ArticleNeurosurgical review2025
Endoscopic endonasal approach for rare sellar/parasellar pathologies: Insights from a neurosurgical perspective.
Article in Neurosurgical review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endoscopic endonasal approach (EEA) has become a well- established approach for skull base pathologies (SBP), providing a minimally invasive corridor to access various lesions. While the technique has been extensively studied for common skull base tumors, data on extremely rare pathologies remain limited. Our study aims to present our experience with rare SBPs managed via the EEA, highlighting the challenges associated with preoperative diagnosis, intraoperative decision-making, and surgical-strategy modifications. A retrospective analysis was conducted on patients who underwent endoscopic endonasal surgery at the tertiary center up to January 2025. Among 6,225 EEA performed, 41 patients with exceptionally rare SBP were identified. Each tumor type was separately evaluated for differences in resection, complication rates, and recurrence patterns. These included 6 pituitary pituicytomas, 5 plasmacytomas, 5 xanthogranulomas, 4 granular cell tumors, 3 giant cell tumors and others. Gross total resection was achieved in 68% of cases, with subtotal resection in vascular or malignant tumors. Intraoperative challenges included unexpected vascularity and fibrotic adhesions. Postoperative CSF leakage occurred in 7%, and recurrence was observed in 17%, mostly in malignant or partially resected tumors. No intraoperative mortality was recorded. Tailored adjuvant treatments ensured durable disease control in most patients. Even in highly experienced centers, rare SBP pose unique diagnostic and surgical challenges. The discrepancy between preoperative and intraoperative findings often necessitates real-time strategic adaptations. In these rare cases, for optimizing patient outcomes requires a comprehensive understanding of skull base anatomy, flexibility in surgical planning, readiness for sudden strategy modifications, and a multidisciplinary approach.
Indexed as
Identifiers
41385139What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.